<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654587</url>
  </required_header>
  <id_info>
    <org_study_id>OSE2101C301</org_study_id>
    <secondary_id>2015-003183-36</secondary_id>
    <nct_id>NCT02654587</nct_id>
  </id_info>
  <brief_title>Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor</brief_title>
  <acronym>ATALANTE 1</acronym>
  <official_title>A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small-Cell Lung Cancer With Progressive Disease After Last Treatment With Immune Checkpoint Inhibitors (ICI). (OSE2101C301)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSE Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OSE Immunotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if the Investigational Medicinal Product Tedopi&#xD;
      (OSE2101) is more effective than standard treatment in treating patients with stage IIIB&#xD;
      NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment&#xD;
      after failure of immune checkpoint-inhibitor regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Step 1 primary objective: Overall Survival rate (approx. 100 patients) / Step 2 primary objective: Overall Survival (approx. 363 patients in total, number to be reassessed based on the step 1 results)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival time (OS)</measure>
    <time_frame>Approx. 24 months</time_frame>
    <description>In Step 1: OS rate at 12 months in experimental Arm A (OSE2101) in 84 evaluable patients exposed to OSE2101&#xD;
In Step 2: comparison of OS between experimental Arm A (OSE2101) and control Arm B (docetaxel or pemetrexed) when 278 events observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 (EORTC QLQ questionnaire): &quot;Global health status/QoL&quot; score based on questions 29</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-LC13 (lung cancer module from EORTC QLQ questionnaire): time to 1st ≥ 10-point deterioration in (question 40), dyspnea (questions 33, 34, 35) or cough (question 31)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR at 12 months (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR) (in Step 1 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability profile compared to the control group</measure>
    <time_frame>Approx. 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective Response Rate (ORR) (In Step 2 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease Control Rate (DCR) at 12 months (In Step 2 only)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DR) (In Step 2 only)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to deterioration (TTD)</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to next lung cancer therapy</measure>
    <time_frame>Approx. 24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>OSE2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.&#xD;
Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.&#xD;
Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSE2101</intervention_name>
    <arm_group_label>OSE2101</arm_group_label>
    <other_name>Tedopi</other_name>
    <other_name>EP-2101</other_name>
    <other_name>EP2101</other_name>
    <other_name>IDM-2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent document indicating that the patient has been&#xD;
             informed of all the pertinent aspects of the trial prior to enrollment.&#xD;
&#xD;
          2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          3. Female or male, 18 years of age or older.&#xD;
&#xD;
          4. Histologically or cytologically proven diagnosis of NSCLC that is locally advanced&#xD;
             (stage III) unsuitable for radiotherapy or metastatic (stage IV) according to the 8th&#xD;
             edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International&#xD;
             Union Against Cancer and the American Joint Committee on Cancer.&#xD;
&#xD;
          5. Subjects with disease recurrence or progression After therapy with an immune&#xD;
             checkpoint inhibitor and platinum-based chemotherapy i) either 1st line chemotherapy&#xD;
             followed by 2nd line checkpoint inhibitor, or ii) 1st line combination of checkpoint&#xD;
             inhibitor and chemotherapy Patients with progression during or within 12 months after&#xD;
             the end of ICI as sequential or concomitant platinum-based chemotherapy ± radiation&#xD;
             for locally advanced disease (stage III) are eligible&#xD;
&#xD;
          6. Subjects with measurable or non-measurable lesions.&#xD;
&#xD;
          7. Subjects must express HLA-A2 phenotype as assessed serologically.&#xD;
&#xD;
          8. Subjects must be considered suitable for chemotherapy with either single-agent&#xD;
             pemetrexed or docetaxel.&#xD;
&#xD;
          9. Subjects with brain metastases are eligible if treated (whole brain radiotherapy,&#xD;
             stereotaxic radiotherapy, surgery) at least 3 weeks prior to initiation of study&#xD;
             treatment and have no symptoms related to brain metastases for at least 2 weeks before&#xD;
             initiation of study treatment and are not taking any forbidden medications.&#xD;
&#xD;
         10. Any prior chemotherapy, immunotherapy, hormonal therapy, radiation therapy or&#xD;
             surgeries must have been completed at least 3 weeks prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
         11. Any toxicity from prior therapy must have recovered to ≤ Grade 1 (except alopecia).&#xD;
&#xD;
         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
         13. Adequate organ function as defined by all the following criteria:&#xD;
&#xD;
               -  Albuminemia &gt; 25g/L&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 1.5 x&#xD;
                  upper limit of normal (ULN) with alkaline phosphatase ≤ 2.5 x ULN, or AST and ALT&#xD;
                  ≤ 5 x ULN if liver function abnormalities are due to liver metastases&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/L&#xD;
&#xD;
               -  Platelets ≥ 100000/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL (in the absence of transfusion within 2 weeks before&#xD;
                  randomization)&#xD;
&#xD;
               -  Creatinine clearance (based on modified Cockcroft-Gault formula) ≥ 45 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine&#xD;
             lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas).&#xD;
&#xD;
          2. Patients with squamous cell carcinoma histology, and who had docetaxel as part of his&#xD;
             prior chemotherapy.&#xD;
&#xD;
          3. Current or previous treatment with investigational therapy in another therapeutic&#xD;
             clinical trial (interrupted less than 4 weeks before study treatment initiation).&#xD;
&#xD;
          4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to&#xD;
             Tyrosine-Kinase Inhibitor (TKI) (EGFR exon 18-21) or Anaplastic Lymphoma Kinase (ALK)&#xD;
             rearrangement.&#xD;
&#xD;
          5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be&#xD;
             scheduled to continue concomitantly to the study).&#xD;
&#xD;
          6. Spinal cord compression (unless treated with the patient attaining good pain control&#xD;
             and stable or recovered neurologic function), carcinomatous meningitis, or&#xD;
             leptomeningeal disease&#xD;
&#xD;
          7. Patients with squamous cell histology or non-squamous cell histology previously&#xD;
             treated by pemetrexed with a contraindication for docetaxel with grade ≥ 2 neuropathy&#xD;
             or hypersensitivity reaction to medications formulated with polysorbate 80 (Tween 80)&#xD;
             as they could be randomly assigned to Arm B.&#xD;
&#xD;
          8. Patients with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications.&#xD;
&#xD;
          9. Treatment with corticosteroids in the last 3-week period before inclusion, except for&#xD;
             topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal&#xD;
             systemic absorption (e.g. with a dose ≤ 500 microgram beclomethasone equivalent for&#xD;
             inhaled steroids), or steroid doses ≤ 10 mg daily prednisone equivalent which are&#xD;
             permitted.&#xD;
&#xD;
         10. A recognized immunodeficiency disease including human immunodeficiency virus (HIV)&#xD;
             infection (and other cellular immunodeficiencies, hypogammaglobulinemia or&#xD;
             dysgammaglobulinemia; subjects who have hereditary, congenital or acquired&#xD;
             immunodeficiencies).&#xD;
&#xD;
         11. Patients with auto-immune disease, with the exception of type I diabetes or treated&#xD;
             hypothyroidism.&#xD;
&#xD;
         12. Patients with interstitial lung disease.&#xD;
&#xD;
         13. Patients with active B or C hepatitis.&#xD;
&#xD;
         14. Other malignancy: patients will not be eligible if they have evidence of other active&#xD;
             invasive cancer(s) (other than NSCLC) within 5 years prior to screening (except&#xD;
             appropriately treated non-melanoma skin cancer or localized cervical cancer, or other&#xD;
             local tumors considered cured (e.g.localized and presumed cured prostate cancer).&#xD;
&#xD;
         15. Other severe acute or chronic medical or psychiatric conditions, or laboratory&#xD;
             abnormalities that would impart, in the judgment of the investigator and/or sponsor,&#xD;
             excess risk associated with study participation or study drug administration, and&#xD;
             which would, therefore, make the patient inappropriate for entry into this study.&#xD;
&#xD;
         16. Female patients must be surgically sterile or be postmenopausal, or must agree to use&#xD;
             effective contraception during the period of the trial and for at least 90 days after&#xD;
             completion of treatment.&#xD;
&#xD;
         17. Male patients sexually active with a woman of childbearing potential must be&#xD;
             surgically sterile or must agree to use effective contraception during the period of&#xD;
             the trial and for at least 90 days after completion of treatment. The decision of&#xD;
             effective contraception will be based on the judgment of the principal investigator.&#xD;
&#xD;
         18. Breastfeeding women.&#xD;
&#xD;
         19. Women with a positive pregnancy test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Valley Hematology and Oncology medical Group</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, Inc</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchartrain Cancer Center</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert W. Franz Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millenium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, Onkologické oddelení</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Všeobecná Fakultní nemocnice</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Saint Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHGU Morvan - Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paoli-Calmettes Institute</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Bégin</name>
      <address>
        <city>Saint Mandé</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Troyes</name>
      <address>
        <city>Troyes</city>
        <zip>10003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy (IGR)</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Mehrheit - Kliniken der Stadt Köln - Lungenklinik</name>
      <address>
        <city>Cologne</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II Hospital Martha-Maria Halle-Dölau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen Medizinische Klinik II</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont II szamu telephely</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet XI Tüdőbelosztály</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Országos Korányi TBC és Pulmonológiai Intézet XIV Tüdőbelosztály</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudományi Kar Pulmonologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Mellkasi Betegsegek Szakkorháza I Tüdőosztály</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matrai Gyogyintézet</name>
      <address>
        <city>Mátraháza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Campus Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9087200</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kefar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin (Belinson) Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia dell'Ospedale Vito Fazzi di Lecce, Piazza Muratore</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia medica</name>
      <address>
        <city>Legnano</city>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda USL 2 Lucca - Dipartimento Oncologico</name>
      <address>
        <city>Lucca</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Pneumologia a indirizzo oncologico, Presidio Ospedaliero Monaldi - Azienda Ospedaliera dei Colli - Via Leonardo Bianchi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto, IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Perugia - Oncologia medica</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O Oncologia ed Ematologia, Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Ospedale Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica, Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia Medica Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>20000128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Onkologii i Radioterapii , Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska &quot;KOMED&quot;</name>
      <address>
        <city>Konin</city>
        <zip>62-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Leczenia chorób Płuc i Gruźlicy</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zespolony , Oddział Chemioterapii Nowotworów</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Quirón Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Complejo Hospitalario Universitario A Coruna (CHUAC)&quot;</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz Servicio de Oncología Médica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda Servicio de Oncología Médica Consultas externas, 2ª planta</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataro</name>
      <address>
        <city>Mataró</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton Keynes Hospital</name>
      <address>
        <city>Milton Keynes</city>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.</citation>
    <PMID>18802154</PMID>
  </reference>
  <reference>
    <citation>Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vaccin. 2008 May-Jun;4(3):210-8. Epub 2010 May 11.</citation>
    <PMID>18382135</PMID>
  </reference>
  <reference>
    <citation>Nemunaitis J, Cunningham, C ,Bender, J, Ishioka, G, Maples, P, Pappen, B, Stephenson, J, Morse, M, Mills, B, Greco, A, McCune, D, Steis, R, Nugent, F, Khong, HT, Richards, D. Phase II trial of a 10-epitope CTL vaccine, IDM-2101, in metastatic NSCLC patients: Induction of immune responses and clinical efficacy. International Society for Biological Therapy of Cancer 2007, p 891-2.</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

